U
AXDX

UBS’s Accelerate Diagnostics AXDX Stock Holding History

UBS’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2.17M Buy
10,108
+1,755
+21% +$341K ﹤0.01% 2834
2014
Q2 		$2.17M Buy
8,353
+1,040
+14% +$227K ﹤0.01% 2791
2014
Q1 		$1.59M Buy
7,313
+3
+0% +$445 ﹤0.01% 3007
2013
Q4 		$892K Buy
7,310
+6,005
+460% +$803K ﹤0.01% 3671
2013
Q3 		$175K Buy
1,305
+501
+62% +$44.7K ﹤0.01% 5343
2013
Q2 		$65K Buy
+804
New +$59.7K ﹤0.01% 6402

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Wood Investment Counsel Denver, Colorado $669M AUM 20.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SM
Selkirk Management Chatham, New Jersey $294M AUM 26.84% 1-Year Est. Return

UBS's AXDX Position: Q3 2014 in Review

UBS increased its Accelerate Diagnostics (AXDX) stake by 21% in Q3 2014, buying an estimated $341K and bringing the position to 10,108 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2834.

UBS first reported a position in AXDX in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.17M in Q2 2014. 71 funds tracked by Wall St. Rank hold AXDX as of Q3 2014.

  • UBS held 10,108 shares of Accelerate Diagnostics worth $2.17M as of Q3 2014.
  • UBS bought 1,755 Accelerate Diagnostics shares in Q3 2014, an estimated $341K.
  • Accelerate Diagnostics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2834 holding.
  • UBS first reported a position in Accelerate Diagnostics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Accelerate Diagnostics position peaked at $2.17M in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.